Paper37589596
Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.
Ouedraogo A and 16 others. J Pediatric Infect Dis Soc, 2023. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. Papers, record 37589596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37589596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Typhoid Fever | Major topic |
| Typhoid-Paratyphoid Vaccines | Major topic |
| Humans | |
| Child | |
| Infant | |
| Vaccines, Conjugate | |
| Burkina Faso | |
| Antibody Formation | |
| Immunoglobulin A | |
| Immunoglobulin G | |
| Antibodies, Bacterial |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| OPP1151153 | Bill and Melinda Gates Foundation | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07624175 | Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso | Background |
Source ClinicalTrials.gov
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34384540 | Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. | Lancet | 2021 | https://conductscience.org/library/papers/34384540 | PubMed |
| 2 | 35961356 | Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. | Lancet Glob Health | 2022 | https://conductscience.org/library/papers/35961356 | PubMed |
| 3 | 28965718 | Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. | Lancet | 2017 | https://conductscience.org/library/papers/28965718 | PubMed |
| 4 | 11320385 | The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11320385 | PubMed |
| 5 | 34625288 | Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination. | Vaccine | 2021 | https://conductscience.org/library/papers/34625288 | PubMed |
| 6 | 25870324 | Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25870324 | PubMed |
| 7 | 24669583 | WHO Expert Committee on Biological Standardization. Sixty-third report. | World Health Organ Tech Rep Ser | 2014 | https://conductscience.org/library/papers/24669583 | PubMed |
| 8 | 33176205 | Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. | Int J Infect Dis | 2021 | https://conductscience.org/library/papers/33176205 | PubMed |
| 9 | 33180929 | Vi-specific serological correlates of protection for typhoid fever. | J Exp Med | 2021 | https://conductscience.org/library/papers/33180929 | PubMed |
| 10 | 34082090 | Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. | Int J Infect Dis | 2021 | https://conductscience.org/library/papers/34082090 | PubMed |
| 11 | 34678198 | Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. | Lancet Glob Health | 2021 | https://conductscience.org/library/papers/34678198 | PubMed |
| 12 | 34525285 | Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34525285 | PubMed |
| 13 | 31781100 | IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. | Front Immunol | 2019 | https://conductscience.org/library/papers/31781100 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41372809 | High prevalence of multi-drug resistant H58 Salmonella Typhi and emerging fluoroquinolone resistance among febrile children in Nairobi County, Kenya. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41372809 | PubMed |
| 40034570 | Immunogenicity and reactogenicity of a booster dose of a typhoid conjugate vaccine (TCV) in Malawian pre-school children. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/40034570 | PubMed |
| 39483419 | Genotypic Diversity among Salmonella Typhi Isolated from Children Living in Informal Settlements in Nairobi, Kenya. | Int J Clin Microbiol | 2024 | https://conductscience.org/library/papers/39483419 | PubMed |
| 39257585 | The use of controlled human infection models to identify correlates of protection for invasive Salmonella vaccines. | Front Immunol | 2024 | https://conductscience.org/library/papers/39257585 | PubMed |
| 39038733 | Longevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan. | Int J Infect Dis | 2024 | https://conductscience.org/library/papers/39038733 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD79A | 973 | PubTator's text mining | https://conductscience.org/library/genes/973 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37589596
GET https://conductscience.org/api/papers/v1/37589596/authors